STABILITY OF CARBOPLATIN IN 5-PERCENT GLUCOSE SOLUTION IN GLASS, POLYETHYLENE AND POLYPROPYLENE CONTAINERS

被引:15
作者
PRAT, J
PUJOL, M
GIRONA, V
MUNOZ, M
SOLE, LA
机构
[1] FAC FARM BARCELONA,UNITAT FIS QUIM,AVGDA DIAGONAL S-N,E-08028 BARCELONA,SPAIN
[2] HOSP GEN VALLE HEBRON,SERV ONCOL,E-08035 BARCELONA,SPAIN
关键词
CARBOPLATIN; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC); STABILITY; DEGRADATION;
D O I
10.1016/0731-7085(94)80013-8
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
The degradation of carboplatin (3.2 mg ml-1) in 5% glucose infusion solution at 25-degrees-C and protected from light was investigated. The effects of the material of the container and temperature were also studied. Solutions were prepared in 5% glucose solution and stored in glass bottles, polyethylene (PE) and polypropylene (PP) containers at 40, 50 and 60-degrees-C and at 25-degrees-C +/- 1-degrees-C. Samples were assayed by an HPLC method to determine the residual carboplatin concentration at each time of sampling. Carboplatin degradation followed pseudo-first-order kinetics and no dependence on the nature of the container was found. After 1 month at 25-degrees(+/- 1-degrees)C the change in carboplatin concentration was <2% of the initial concentration in 5% glucose. These results are in agreement with those predicted by the application of the Arrhenius equation.
引用
收藏
页码:81 / 84
页数:4
相关论文
共 6 条
[1]   STABILITY OF CISPLATIN, IPROPLATIN, CARBOPLATIN, AND TETRAPLATIN IN COMMONLY USED INTRAVENOUS SOLUTIONS [J].
CHEUNG, YW ;
CRADOCK, JC ;
VISHNUVAJJALA, BR ;
FLORA, KP .
AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1987, 44 (01) :124-130
[2]  
DEBOLOS J, 1986, IL FARMACO, V8, P255
[3]  
GARRETT ER, 1962, J PHARM SCI, V9, P811
[4]   HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY OF INORGANIC PLATINUM(II) COMPLEXES USING SOLVENT-GENERATED ANION-EXCHANGERS .2. THE EFFECT OF ELECTROLYTES ON SOLUTE RETENTION [J].
RILEY, CM ;
STERNSON, LA ;
REPTA, AJ .
JOURNAL OF CHROMATOGRAPHY, 1981, 219 (02) :235-244
[5]  
RILEY CM, 1986, ANAL PROFILES DRUG S, V14, P77
[6]  
VANECHO DA, 1984, CANCER TREAT REP, V68, P1103